UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Diffuse Midline Glioma
Glioma
Brainstem Glioma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
This phase 1 clinical trial studies how well the drug AZD1390 works in combination with radiation therapy to treat pediatric high-grade glioma, diffuse midline glioma, or diffuse intrinsic pontine glioma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I/IIa study in patients with recurrent IDH-mutant glioma will investigate the safety and preliminary efficacy of AZD9574 in combination with temozolomide.
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This non-therapeutic study aims to collect prospective neurocognitive and imaging data before, during, and after surgery.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This study will evaluate the feasibility and efficacy of various cognitive rehabilitation treatments in patients with grade II-III glioma.
Conditions
Glioma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy of safusidenib in newly diagnosed high-grade IDH-mutant astrocytoma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Neurofibromatosis type 1
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Summary
This phase II clinical trial will evaluate the efficacy and side effects of larotrectinib in treating patients with previously untreated TRK fusion solid tumors (including central nervous system (CNS) tumors) and relapsed TRK fusion acute leukemia.
Conditions
Glioma
Astrocytoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant glioma.
Conditions
Glioma
Astrocytoma
Oligodendroglioma
Ependymoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
This is a pilot study to develop a liquid biomarker of hypermutation in glioma patients previously treated with the chemotherapy temozolomide.